- Home
- WDC vs NVO Comparison
WDC vs NVO Comparison
Compare WDC & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDC | NVO |
|---|---|---|
| Founded | 1970 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.2B | 218.9B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | WDC | NVO |
|---|---|---|
| Price | $513.16 | $50.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 11 |
| Target Price | ★ $281.77 | $51.00 |
| AVG Volume (30 Days) | 8.2M | ★ 9.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 0.12% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | ★ 16.05 | N/A |
| Revenue | ★ $9,520,000,000.00 | N/A |
| Revenue This Year | $32.24 | N/A |
| Revenue Next Year | $26.55 | $3.70 |
| P/E Ratio | $34.90 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.04 | $35.12 |
| 52 Week High | $799.87 | $71.80 |
Technical Indicators
Market Signals| Indicator | WDC | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 67.26 |
| Support Level | $475.08 | $43.14 |
| Resistance Level | $525.15 | $53.63 |
| Average True Range (ATR) | 46.07 | 1.03 |
| MACD | -14.22 | 0.05 |
| Stochastic Oscillator | 8.74 | 87.66 |
Price Performance
Historical ComparisonAbout WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.